Search Medical Condition
Please enter condition
Please choose location
 

Hypoparathyroidism Clinical Trials

A listing of Hypoparathyroidism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

We are looking for adults 18 years of age and older with hypoparathyroidism (at time of consent) to take part in a clinical research study. The purpose of the PARALLAX Study is to measure the safety and tolerability of an injectable study drug and its effects on calcium levels in ...

Phase

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Subjects With Hypoparathyroidism

This study is being conducted to characterize the effects of twice daily administration of rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and tolerability over the course of 24 hours as compared with the current once daily dosing regimen of marketed rhPTH(1-84) (marketed ...

Phase

Resistance to Vitamin D or Parathyroid Hormone

Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis and treatment and for inclusion in other protocols. These states include hypocalcemia, rickets, osteomalacia, pseudohypoparathyroidism. Resistance to a factor is manifested by deficient bioeffect despite high levels of the factor ...

Phase N/A

Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism

Background Hypoparathyroidism (HypoPT) is a group of rare clinical disorders characterized by hypocalcaemia and hyperphosphatemia with inappropriate low levels of parathyroid hormone (PTH). Due to the lack of PTH, the renal production of 1,25-dihydroxycholecalciferol (1,25(OH)2D) is reduced. Most often, HypoPT is caused by accidental removal of the parathyroid glands during ...

Phase N/A

A Registry for Patients With Chronic Hypoparathyroidism

This is a prospective, observational disease and drug registry designed to evaluate the safety and effectiveness profile of rhPTH(1-84) under conditions of routine clinical practice and to observe the clinical course of chronic hypoparathyrodism. No treatment is provided as a result of participating in this registry and all decisions on ...

Phase N/A

Intraoperative Monitoring to Predict Postoperative Complications After Thyroidectomy

Intraoperative PTH values and intraoperative continuous neuromonitoring will be collected prospectively in consecutive patients who undergo total thyroidectomy. Postoperative parathyroid morbidity and recurrent laryngeal nerve morbidity will be evaluated within 1 week after total thyroidectomy and at 1 year postoperatively. Other postoperative morbidity will be evaluated at 1 year postoperatively ...

Phase N/A

Survey on Epidemiology of Hypoparathyroidism in France

Very few data has been published on the epidemiology of hypoparathyroidism worldwide. None exists specifically in France. Hypoparathyroidism could led to complications: e.g. symptomatic hypocalcemia, calcifications (brain, eye and other soft tissues), nephrolithiasis/nephrocalcinosis, renal insufficiency. Here,the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in ...

Phase N/A

Albright Hereditary Osteodystrophy: Natural History Growth and Cognitive/Behavioral Assessments

Pseudohypoparathyroidism type 1a (PHP1a) is a disorder that causes many endocrine and developmental problems. To date, medical treatment has focused primarily on maintenance of normal serum levels of calcium, phosphorous, and thyroid hormone. However, these therapeutic interventions do not address the problems of short stature, obesity, and subcutaneous ossifications, which ...

Phase N/A

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

The design consists in a five-periods, two-treatments, open-label, randomized, crossover study with blind end-point evaluation. Patients will come for an inclusion visit and will receive treatment with 0.5 g/day alfacalcidol for 4 weeks (283 days, run-in). They will be instructed to maintain dietary calcium intakes (1 g/day) for the duration ...

Phase

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

This protocol is a natural history study designed to investigate the clinical, microbiologic, genetic and immunologic correlates of primary immune deficiencies and other conditions associated with mucocutaneous and invasive fungal infections (IFIs). The hypothesis is that chronic mucocutaneous mycoses and IFIs are caused by abnormalities in immune function in these ...

Phase N/A